Intrathecal Administration of Baclofen (ITB) to Cerebral Palsy Patients With Therapy-Resistant Spasticity

Intrathecal Administration of Baclofen (ITB) to Cerebral Palsy Patients With Therapy-Resistant Spasticity

Evaluation of the effect of intrathecal administration of Baclofen on spasticity of cerebral palsy patients, by means of standardized and internationally accepted scales

Evaluation of the effect of intrathecal administration of Baclofen on spasticity of cerebral palsy patients, by means of standardized and internationally accepted scales

Inclusion Criteria:

• CP patients with therapy-resistent spasticity
• Patients with sufficient body weight in relation to the volume
• Oral medication has failed: insufficient effect or too many side-effects
• The patient and family understand the objectives of the treatment and accept those objectives
• Informed Consent

Exclusion Criteria:

• Contra-indications for surgery (e.g. infection)
• Hypersensitivity to oral Baclofen